RecruitingNCT06146660

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Sponsor

Bristol-Myers Squibb

Enrollment

600 participants

Start Date

Jul 24, 2024

Study Type

OBSERVATIONAL

Conditions

Obstructive Hypertrophic Cardiomyopathy

Summary

The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.

Eligibility

Min Age: 19 Years

Inclusion Criteria3

Adult participants 19 years of age or older
Participants who receive mavacamten according to the approved product label
Participants who sign the informed consent form

Exclusion Criteria2

Participants who are prescribed mavacamten for therapeutic indications not approved in Korea
Participants for whom mavacamten is contraindicated as clarified in Korean prescribing information approved by the Ministry of Food and Drug Safety

Interested in this trial?

Get notified about updates and connect with the research team.